Join the Amifampridine group to help and get support from people like you.
Amifampridine News
Catalyst Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for Firdapse Expanding Patient Population to Include Pediatric Patients
Firdapse is Now a Treatment Option for All LEMS Patients 6 Years of Age and Older in the U.S. CORAL GABLES, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) – Catalyst Pharmaceuticals, Inc. ("Catalyst")...
FDA Medwatch Alert: Jacobus Pharmaceutical Company Inc. Issues Voluntary Worldwide Recall of Ruzurgi (amifampridine) 10 mg Tablets Due to Yeast, Mold, and Bacterial Contamination
September 13, 2021 – Plainsboro, New Jersey, Jacobus Pharmaceutical Company Inc. is voluntarily recalling 3 lots of Ruzurgi® (amifampridine) 10 mg tablets to the consumer level. The products have ...
FDA Approves Ruzurgi (amifampridine) for Children with Lambert-Eaton Myasthenic Syndrome
May 06, 2019 – The U.S. Food and Drug Administration today approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years to less than 17...
FDA Approves Firdapse (amifampridine) for Lambert-Eaton Myasthenic Syndrome
November 28, 2018 – The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a rare...
Ask a question
To post your own question to this support group, sign in or create an account.